FMC and Corteva Partner to Expand Access to Fluindapyr Fungicide

FMC Corporation and Corteva Agriscience have partnered to expand the use of FMC's fluindapyr fungicide in the U.S. corn and soybean markets, targeting foliar diseases. Under the agreement, both companies will market fluindapyr-based products, with Corteva planning to launch its product in 2026, pending EPA approval. Despite this partnership, FMC maintains its 2025 revenue outlook at $4.15-$4.35 billion and adjusted EPS outlook of $3.26-$3.70, both essentially flat year-over-year, while FMC shares have declined 29.7% in the past six months.

Analysis

FMC Corporation has entered into a strategic partnership with Corteva Agriscience aimed at expanding the market reach of its fluindapyr fungicide technology within the substantial U.S. corn and soybean markets, which collectively represent approximately 175 million planted acres. This collaboration will see both entities market fluindapyr-based products, with Corteva anticipated to launch its offering in the 2026 growing season, contingent upon EPA regulatory approval. Fluindapyr is positioned as an innovative solution offering long-lasting residual control against challenging foliar diseases, including those resistant to other fungicides. Despite this potentially positive long-term development for its proprietary technology, FMC's shares have significantly underperformed, declining 29.7% over the past six months compared to a 1.2% dip for its industry. The company's first-quarter guidance for 2025 projects essentially flat year-over-year revenue at a midpoint of $4.25 billion and adjusted earnings per share at a midpoint of $3.48. Adjusted EBITDA is forecasted at $870-$950 million, a modest 1% increase at the midpoint (or 4% excluding GSS divestiture), which incorporates an estimated $15-$20 million in incremental tariff costs. The current financial outlook and recent stock performance present a mixed picture against the backdrop of this strategic agricultural partnership.

Key Decisions for Investors

• Investors should view the FMC-Corteva partnership as a positive long-term catalyst for fluindapyr sales and market penetration, though material financial impact from Corteva's product launch is not expected until 2026 and is subject to EPA approval.
• Given FMC's maintained flat revenue and EPS guidance for 2025 and significant recent share price underperformance, a cautious approach may be warranted in the near term, closely monitoring execution and market conditions.
• Key catalysts to watch include progress on Corteva's EPA registration for its fluindapyr product, FMC's own pipeline developments for fluindapyr-based products, and any shifts in agricultural input demand or pricing that could affect FMC's financial performance beyond current guidance.